Glaukos (GKOS) investor relations material

Strategic position

• Hybrid pharmaceutical-device model focused on chronic eye diseases, dropless therapies and underserved patient populations.

• Growth opportunities center on interventional glaucoma, which aims to reduce drug burden, and interventional keratoconus, which targets earlier diagnosis and improved access to care.

Interventional glaucoma

• Topical-drop non-compliance is a major care challenge: 90% of patients are non-compliant, and 50% purposely discontinue drops within 6 months.

• iDose TR is a 75 mcg intracameral travoprost implant designed for up to 3 years of therapy; FDA-approved for re-administration in Jan 2026.

• At 12 months, 81% of iDose TR subjects were free of IOP-lowering drops; at 3 years, 70% were controlled on the same or fewer meds. Phase 3 analysis showed non-inferiority to topical timolol at 3 years.

• iDose TRIO completed patient enrollment in a Phase 3b study; iDose TREX Phase 2a results showed mean IOP reductions of 8.6–10.8 mmHg, with Phase 2b/3 development advancing.

• iStent infinite offers up to 240° of outflow coverage; its platform has 14 years of commercial MIGS leadership and 400+ peer-reviewed publications.

Interventional keratoconus

• Keratoconus often begins in the teenage years; ~90% of cases are bilateral, and ~20% of untreated patients ultimately require corneal transplant.

• Fewer than 1 in 5 newly diagnosed progressive KC eyes currently receive Photrexa; 70% of diagnosed patients had Stage 2 or worse disease, while 40% declined or significantly delayed therapy.

• Epioxa is the first and only FDA-approved epithelium-on treatment: incision-free topical drug therapy designed to slow or halt progression with one administration; commercially available from March 2026.

• A patient-access buildout includes service and support, site-of-care and payer networks, provider awareness, and a disease-awareness campaign with Stephen Curry.

• Customized third-generation iLink is in Phase 2, using corneal tomography and targeted UV energy to tailor treatment; iVeena is also in Phase 2.